치료용 혈장 교환 시장 : 세계 업계 분석, 규모, 점유율, 수량, 성장, 동향, 예측(2023-2031년)

Therapeutic Plasma Exchange Market - Scope of Report

TMR's report on the global therapeutic plasma exchange market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global therapeutic plasma exchange market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global therapeutic plasma exchange market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the therapeutic plasma exchange market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global therapeutic plasma exchange market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global therapeutic plasma exchange market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global therapeutic plasma exchange market.

The report delves into the competitive landscape of the global therapeutic plasma exchange market. Key players operating in the global therapeutic plasma exchange market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global therapeutic plasma exchange market profiled in this report.

Key Questions Answered in Global therapeutic plasma exchange Market Report:

• What is the sales/revenue generated by therapeutic plasma exchange across all regions during the forecast period?
• What are the opportunities in the global therapeutic plasma exchange market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Therapeutic Plasma Exchange Market - Research Objectives and Research Approach

The comprehensive report on the global therapeutic plasma exchange market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global therapeutic plasma exchange market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global therapeutic plasma exchange market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Therapeutic Plasma Exchange Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Product Definition
  • 4.1.2. Industry Evolution/Developments
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Therapeutic Plasma Exchange Market Analysis and Forecast, 2023-2031

5. Key Insights

• 5.1. Pipeline Analysis
• 5.2. Key Product/Brand Analysis
• 5.3. Key Mergers & Acquisitions
• 5.4. COVID-19 Pandemic Impact on Industry

6. Global Therapeutic Plasma Exchange Market Analysis and Forecast, by Disease Indication

• 6.1. Introduction & Definition
• 6.2. Key Findings/Developments
• 6.3. Market Value Forecast, by Disease Indication, 2023-2031
  • 6.3.1. Neurological Disorders
    • 6.3.1.1. Chronic Inflammatory Demyelinating Polyneuropathy
    • 6.3.1.2. Myasthenia Gravis
    • 6.3.1.3. Multiple Sclerosis
    • 6.3.1.4. Neuromyelitis Optica
    • 6.3.1.5. Guillain-Barre Syndrome
  • 6.3.2. Renal Disorders
    • 6.3.2.1. Post-renal Transplant Rejection
    • 6.3.2.2. Anti-glomerular Basement Membrane (GBM) Disease
    • 6.3.2.3. Wegener's Granulomatosis
  • 6.3.3. Hematology Disorders
    • 6.3.3.1. Thrombotic Thrombocytopenic Purpura
    • 6.3.3.2. Hemolytic Uremic Syndrome
    • 6.3.3.3. Cryoglobulinemia
    • 6.3.3.4. Multiple Myeloma
    • 6.3.3.5. Metabolic Disorders
    • 6.3.3.6. Homozygous Familial Hypercholesterolemia
    • 6.3.3.7. Fulminant Wilson's Disease
  • 6.3.4. Others
• 6.4. Market Attractiveness Analysis, by Disease Indication

7. Global Therapeutic Plasma Exchange Market Analysis and Forecast, by End-user

• 7.1. Introduction & Definition
• 7.2. Key Findings/Developments
• 7.3. Market Value Forecast, by End-user, 2023-2031
  • 7.3.1. Hospitals
  • 7.3.2. Specialty Clinics
  • 7.3.3. Ambulatory Surgical Centers
• 7.4. Market Attractiveness Analysis, by End-user

8. Global Therapeutic Plasma Exchange Market Analysis and Forecast, by Region

• 8.1. Key Findings
• 8.2. Market Value Forecast, by Region, 2023-2031
  • 8.2.1. North America
  • 8.2.2. Europe
  • 8.2.3. Asia Pacific
  • 8.2.4. Latin America
  • 8.2.5. Middle East & Africa
• 8.3. Market Attractiveness Analysis, by Region

9. North America Therapeutic Plasma Exchange Market Analysis and Forecast

• 9.1. Introduction
• 9.2. Key Findings
• 9.3. Market Value Forecast, by Disease Indication, 2023-2031
  • 9.3.1. Neurological Disorders
    • 9.3.1.1. Chronic Inflammatory Demyelinating Polyneuropathy
    • 9.3.1.2. Myasthenia Gravis
    • 9.3.1.3. Multiple Sclerosis
    • 9.3.1.4. Neuromyelitis Optica
    • 9.3.1.5. Guillain-Barre Syndrome
  • 9.3.2. Renal Disorders
    • 9.3.2.1. Post-renal Transplant Rejection
    • 9.3.2.2. Anti-glomerular Basement Membrane (GBM) Disease
    • 9.3.2.3. Wegener's Granulomatosis
  • 9.3.3. Hematology Disorders
    • 9.3.3.1. Thrombotic Thrombocytopenic Purpura
    • 9.3.3.2. Hemolytic Uremic Syndrome
    • 9.3.3.3. Cryoglobulinemia
    • 9.3.3.4. Multiple Myeloma
    • 9.3.3.5. Metabolic Disorders
    • 9.3.3.6. Homozygous Familial Hypercholesterolemia
    • 9.3.3.7. Fulminant Wilson's Disease
  • 9.3.4. Others
• 9.4. Market Value Forecast, by End-user, 2023-2031
  • 9.4.1. Hospitals
  • 9.4.2. Specialty Clinics
  • 9.4.3. Ambulatory Surgical Centers
• 9.5. Market Value Forecast, by Country, 2023-2031
  • 9.5.1. U.S.
  • 9.5.2. Canada
• 9.6. Market Attractiveness Analysis
  • 9.6.1. By Disease Indication
  • 9.6.2. By End-user
  • 9.6.3. By Country

10. Europe Therapeutic Plasma Exchange Market Analysis and Forecast

• 10.1. Introduction
• 10.2. Key Findings
• 10.3. Market Value Forecast, by Disease Indication, 2023-2031
  • 10.3.1. Neurological Disorders
    • 10.3.1.1. Chronic Inflammatory Demyelinating Polyneuropathy
    • 10.3.1.2. Myasthenia Gravis
    • 10.3.1.3. Multiple Sclerosis
    • 10.3.1.4. Neuromyelitis Optica
    • 10.3.1.5. Guillain-Barre Syndrome
  • 10.3.2. Renal Disorders
    • 10.3.2.1. Post-renal Transplant Rejection
    • 10.3.2.2. Anti-glomerular Basement Membrane (GBM) Disease
    • 10.3.2.3. Wegener's Granulomatosis
  • 10.3.3. Hematology Disorders
    • 10.3.3.1. Thrombotic Thrombocytopenic Purpura
    • 10.3.3.2. Hemolytic Uremic Syndrome
    • 10.3.3.3. Cryoglobulinemia
    • 10.3.3.4. Multiple Myeloma
    • 10.3.3.5. Metabolic Disorders
    • 10.3.3.6. Homozygous Familial Hypercholesterolemia
    • 10.3.3.7. Fulminant Wilson's Disease
  • 10.3.4. Others
• 10.4. Market Value Forecast, by End-user, 2023-2031
  • 10.4.1. Hospitals
  • 10.4.2. Specialty Clinics
  • 10.4.3. Ambulatory Surgical Centers
  • 10.4.4. Others
• 10.5. Market Value Forecast, by Country/Sub-region, 2023-2031
  • 10.5.1. Germany
  • 10.5.2. U.K.
  • 10.5.3. France
  • 10.5.4. Italy
  • 10.5.5. Spain
  • 10.5.6. Rest of Europe
• 10.6. Market Attractiveness Analysis
  • 10.6.1. By Disease Indication
  • 10.6.2. By End-user
  • 10.6.3. By Country/Sub-region

11. Asia Pacific Therapeutic Plasma Exchange Market Analysis and Forecast

• 11.1. Introduction
• 11.2. Key Findings
• 11.3. Market Value Forecast, by Disease Indication, 2023-2031
  • 11.3.1. Neurological Disorders
    • 11.3.1.1. Chronic Inflammatory Demyelinating Polyneuropathy
    • 11.3.1.2. Myasthenia Gravis
    • 11.3.1.3. Multiple Sclerosis
    • 11.3.1.4. Neuromyelitis Optica
    • 11.3.1.5. Guillain-Barre Syndrome
  • 11.3.2. Renal Disorders
    • 11.3.2.1. Post-renal Transplant Rejection
    • 11.3.2.2. Anti-glomerular Basement Membrane (GBM) Disease
    • 11.3.2.3. Wegener's Granulomatosis
  • 11.3.3. Hematology Disorders
    • 11.3.3.1. Thrombotic Thrombocytopenic Purpura
    • 11.3.3.2. Hemolytic Uremic Syndrome
    • 11.3.3.3. Cryoglobulinemia
    • 11.3.3.4. Multiple Myeloma
    • 11.3.3.5. Metabolic Disorders
    • 11.3.3.6. Homozygous Familial Hypercholesterolemia
    • 11.3.3.7. Fulminant Wilson's Disease
  • 11.3.4. Others
• 11.4. Market Value Forecast, by End-user, 2023-2031
  • 11.4.1. Hospitals
  • 11.4.2. Specialty Clinics
  • 11.4.3. Ambulatory Surgical Centers
  • 11.4.4. Others
• 11.5. Market Value Forecast, by Country/Sub-region, 2023-2031
  • 11.5.1. China
  • 11.5.2. Japan
  • 11.5.3. India
  • 11.5.4. Australia & New Zealand
  • 11.5.5. Rest of Asia Pacific
• 11.6. Market Attractiveness Analysis
  • 11.6.1. By Disease Indication
  • 11.6.2. By End-user
  • 11.6.3. By Country/Sub-region

12. Latin America Therapeutic Plasma Exchange Market Analysis and Forecast

• 12.1. Introduction
• 12.2. Key Findings
• 12.3. Market Value Forecast, by Disease Indication, 2023-2031
  • 12.3.1. Neurological Disorders
    • 12.3.1.1. Chronic Inflammatory Demyelinating Polyneuropathy
    • 12.3.1.2. Myasthenia Gravis
    • 12.3.1.3. Multiple Sclerosis
    • 12.3.1.4. Neuromyelitis Optica
    • 12.3.1.5. Guillain-Barre Syndrome
  • 12.3.2. Renal Disorders
    • 12.3.2.1. Post-renal Transplant Rejection
    • 12.3.2.2. Anti-glomerular Basement Membrane (GBM) Disease
    • 12.3.2.3. Wegener's Granulomatosis
  • 12.3.3. Hematology Disorders
    • 12.3.3.1. Thrombotic Thrombocytopenic Purpura
    • 12.3.3.2. Hemolytic Uremic Syndrome
    • 12.3.3.3. Cryoglobulinemia
    • 12.3.3.4. Multiple Myeloma
    • 12.3.3.5. Metabolic Disorders
    • 12.3.3.6. Homozygous Familial Hypercholesterolemia
    • 12.3.3.7. Fulminant Wilson's Disease
  • 12.3.4. Others
• 12.4. Market Value Forecast, by End-user, 2023-2031
  • 12.4.1. Hospitals
  • 12.4.2. Specialty Clinics
  • 12.4.3. Ambulatory Surgical Centers
  • 12.4.4. Others
• 12.5. Market Value Forecast, by Country/Sub-region, 2023-2031
  • 12.5.1. Brazil
  • 12.5.2. Mexico
  • 12.5.3. Rest of Latin America
• 12.6. Market Attractiveness Analysis
  • 12.6.1. By Disease Indication
  • 12.6.2. By End-user
  • 12.6.3. By Country/Sub-region

13. Middle East & Africa Therapeutic Plasma Exchange Market Analysis and Forecast

• 13.1. Introduction
• 13.2. Key Findings
• 13.3. Market Value Forecast, by Disease Indication, 2023-2031
  • 13.3.1. Neurological Disorders
    • 13.3.1.1. Chronic Inflammatory Demyelinating Polyneuropathy
    • 13.3.1.2. Myasthenia Gravis
    • 13.3.1.3. Multiple Sclerosis
    • 13.3.1.4. Neuromyelitis Optica
    • 13.3.1.5. Guillain-Barre Syndrome
  • 13.3.2. Renal Disorders
    • 13.3.2.1. Post-renal Transplant Rejection
    • 13.3.2.2. Anti-glomerular Basement Membrane (GBM) Disease
    • 13.3.2.3. Wegener's Granulomatosis
  • 13.3.3. Hematology Disorders
    • 13.3.3.1. Thrombotic Thrombocytopenic Purpura
    • 13.3.3.2. Hemolytic Uremic Syndrome
    • 13.3.3.3. Cryoglobulinemia
    • 13.3.3.4. Multiple Myeloma
    • 13.3.3.5. Metabolic Disorders
    • 13.3.3.6. Homozygous Familial Hypercholesterolemia
    • 13.3.3.7. Fulminant Wilson's Disease
  • 13.3.4. Others
• 13.4. Market Value Forecast, by End-user, 2023-2031
  • 13.4.1. Hospitals
  • 13.4.2. Specialty Clinics
  • 13.4.3. Ambulatory Surgical Centers
  • 13.4.4. Others
• 13.5. Market Value Forecast, by Country/Sub-region, 2023-2031
  • 13.5.1. GCC Countries
  • 13.5.2. South Africa
  • 13.5.3. Rest of Middle East & Africa
• 13.6. Market Attractiveness Analysis
  • 13.6.1. By Disease Indication
  • 13.6.2. By End-user
  • 13.6.3. By Country/Sub-region

14. Competition Landscape

• 14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
• 14.2. Market Share Analysis, by Company (2022)
• 14.3. Company Profiles
  • 14.3.1. Asahi Kasei Corporation
    • 14.3.1.1. Company Overview
    • 14.3.1.2. Product Portfolio
    • 14.3.1.3. SWOT Analysis
    • 14.3.1.4. Financial Overview
    • 14.3.1.5. Strategic Overview
  • 14.3.2. Baxter International, Inc.
    • 14.3.2.1. Company Overview
    • 14.3.2.2. Product Portfolio
    • 14.3.2.3. SWOT Analysis
    • 14.3.2.4. Financial Overview
    • 14.3.2.5. Strategic Overview
  • 14.3.3. Terumo Corporation
    • 14.3.3.1. Company Overview
    • 14.3.3.2. Product Portfolio
    • 14.3.3.3. SWOT Analysis
    • 14.3.3.4. Financial Overview
    • 14.3.3.5. Strategic Overview
  • 14.3.4. B. Braun SE
    • 14.3.4.1. Company Overview
    • 14.3.4.2. Product Portfolio
    • 14.3.4.3. SWOT Analysis
    • 14.3.4.4. Financial Overview
    • 14.3.4.5. Strategic Overview
  • 14.3.5. Fresenius Kabi AG
    • 14.3.5.1. Company Overview
    • 14.3.5.2. Product Portfolio
    • 14.3.5.3. SWOT Analysis
    • 14.3.5.4. Financial Overview
    • 14.3.5.5. Strategic Overview
  • 14.3.6. SB-Kawasumi Laboratories, Inc.
    • 14.3.6.1. Company Overview
    • 14.3.6.2. Product Portfolio
    • 14.3.6.3. SWOT Analysis
    • 14.3.6.4. Financial Overview
    • 14.3.6.5. Strategic Overview
  • 14.3.7. Haemonetics Corporation
    • 14.3.7.1. Company Overview
    • 14.3.7.2. Product Portfolio
    • 14.3.7.3. SWOT Analysis
    • 14.3.7.4. Financial Overview
    • 14.3.7.5. Strategic Overview
  • 14.3.8. Cerus Corporation
    • 14.3.8.1. Company Overview
    • 14.3.8.2. Product Portfolio
    • 14.3.8.3. SWOT Analysis
    • 14.3.8.4. Financial Overview
    • 14.3.8.5. Strategic Overview
  • 14.3.9. Charles River Laboratories
    • 14.3.9.1. Company Overview
    • 14.3.9.2. Product Portfolio
    • 14.3.9.3. SWOT Analysis
    • 14.3.9.4. Financial Overview
    • 14.3.9.5. Strategic Overview
  • 14.3.10. Medica S.p.A.
    • 14.3.10.1. Company Overview
    • 14.3.10.2. Product Portfolio
    • 14.3.10.3. SWOT Analysis
    • 14.3.10.4. Financial Overview
    • 14.3.10.5. Strategic Overview